Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
| Buy | Overweight | Hold | Underweight | Sell |
|---|---|---|---|---|
| 4 | 0 | 0 | 0 | 0 |
Analyst Firms Making Recommendations1
- HC Wainwright & Co.
- BTIG
- Mizuho
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for CASI Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 11/15/2023 | CASI | Buy Now | CASI Pharmaceuticals | $5.60 | 114.29% | HC Wainwright & Co. | Sean Lee | $10 → $12 | Maintains | Buy | Get Alert |
| 08/14/2023 | CASI | Buy Now | CASI Pharmaceuticals | $5.60 | 78.57% | HC Wainwright & Co. | Sean Lee | → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2023 | CASI | Buy Now | CASI Pharmaceuticals | $5.60 | 78.57% | HC Wainwright & Co. | Sean Lee | → $10 | Reiterates | Buy → Buy | Get Alert |
| 11/16/2022 | CASI | Buy Now | CASI Pharmaceuticals | $5.60 | 78.57% | BTIG | Justin Zelin | $21 → $10 | Maintains | Buy | Get Alert |
| 11/15/2022 | CASI | Buy Now | CASI Pharmaceuticals | $5.60 | 78.57% | HC Wainwright & Co. | Sean Lee | $12 → $10 | Maintains | Buy | Get Alert |
| 08/15/2022 | CASI | Buy Now | CASI Pharmaceuticals | $5.60 | 114.29% | HC Wainwright & Co. | Swayampakula Ramakanth | $3 → $12 | Maintains | Buy | Get Alert |
| 06/03/2022 | CASI | Buy Now | CASI Pharmaceuticals | $5.60 | 275% | BTIG | Justin Zelin | $4 → $21 | Maintains | Buy | Get Alert |
| 05/16/2022 | CASI | Buy Now | CASI Pharmaceuticals | $5.60 | -46.43% | HC Wainwright & Co. | Sean Lee | $40 → $30 | Maintains | Buy | Get Alert |
| 05/18/2021 | CASI | Buy Now | CASI Pharmaceuticals | $5.60 | -28.57% | BTIG | Justin Zelin | — | Initiates | → Buy | Get Alert |
| 05/14/2021 | CASI | Buy Now | CASI Pharmaceuticals | $5.60 | -28.57% | HC Wainwright & Co. | Sean Lee | — | Maintains | Buy | Get Alert |
| 04/26/2021 | CASI | Buy Now | CASI Pharmaceuticals | $5.60 | -32.14% | Mizuho | Difei Yang | — | Initiates | → Buy | Get Alert |
What is the target price for CASI Pharmaceuticals (CASI)?
The latest price target for CASI Pharmaceuticals (NASDAQ: CASI) was reported by HC Wainwright & Co. on November 15, 2023. The analyst firm set a price target for $12.00 expecting CASI to rise to within 12 months (a possible 114.29% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CASI Pharmaceuticals (CASI)?
The latest analyst rating for CASI Pharmaceuticals (NASDAQ: CASI) was provided by HC Wainwright & Co., and CASI Pharmaceuticals maintained their buy rating.
When is the next analyst rating going to be posted or updated for CASI Pharmaceuticals (CASI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CASI Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CASI Pharmaceuticals was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
Is the Analyst Rating CASI Pharmaceuticals (CASI) correct?
While ratings are subjective and will change, the latest CASI Pharmaceuticals (CASI) rating was a maintained with a price target of $10.00 to $12.00. The current price CASI Pharmaceuticals (CASI) is trading at is $5.60, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.